Affiliation:
1. Rostov regional clinical hospital;
Rostov state medical University of the Ministry of health of the Russian Federation
2. Rostov state medical University of the Ministry of health of the Russian Federation
3. Rostov regional clinical hospital
Abstract
Objectives: to analyze the results of echocardiography 1 year after STEMI in patients undergoing pharmaco-invasive reperfusion using various thrombolytic drugs.Materials and Methods: 240 patients with STEMI after pharmaco-invasive reperfusion were included in an open-label prospective cohort study. Depending on the thrombolytic agent used, the patients were divided into 4 groups: in the 1st (n = 73) — lysis was performed with alteplase; in the 2nd (n = 40) — tenecteplase; in the 3rd (n = 95) — forteplase; in the 4th (n = 32) — streptokinase. Depending on the fibrin-specificity of the thrombolytic, all patients were presented with 2 groups: the group of fibrin-specific thrombolytics (FST, n = 208) and the group of fibrin-nonspecific streptokinase (FNST, n = 32). Echocardiography was assessed 1 year after reperfusion.Results: after 1 year, there was a slight violation of the global LV systolic function, while the EF between the groups did not differ (p = 0.420). A higher EF was recorded in the FST group compared with FNST (49.8 ± 7.4 % versus 47.4 ± 6.8 %; p = 0.048). After 1 year, violations and local LV contractility persisted in each of the four groups (p = 0.161). At the same time, lower WMSI were recorded in the FST group compared to FNST (1.19 [1.06; 1.38] versus 1.25 [1.175; 1.5]; p = 0.029). In the FST group, significantly lower iEDV were recorded (p = 0.048), and iESV (p = 0.022) and LA size (p = 0.007) compared with FNST. In dynamics, 1 year after reperfusion in the FST group, there was a significant increase in EF by 5.5 % (p = 0.000) and a decrease in LV WMSI by 5 % (p = 0.000) compared with the FNST group.Conclusions: pharmaco-invasive treatment of STEMI with the use of thrombolytic drugs after 1 year of follow-up is characterized by comparable echocardiography parameters. After 1 year of follow-up, patients undergoing pharmaco-invasive treatment with fibrin-specific drugs had significantly higher EF, as well as lower WMSI, iEDV, iESV, and LA size compared to fibrin-nonspecific streptokinase.
Publisher
Rostov State Medical University
Reference14 articles.
1. Rudenko B. A. Modern trends in the development of reperfusion therapy in patients with acute coronary syndrome with St segment elevation / B. A. Rudenko, A. S. Shanoyan, S. A. Boytsov // International journal of interventional Cardioangiology, 2014, no. 39, Pp. 31-36.
2. Bainey K.R. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice / K.R. Bainey, P.W. Armstrong, Y. Zheng [et al.] // Circ. Cardiovasc. Interv. – 2019. – Vol. 12. – P. e008059.
3. Larson D.M. Reperfusion Options for ST Elevation Myocardial Infarction Patients with Expected Delays to Percutaneous Coronary Intervention / D.M. Larson, P. McKavanagh, T.D. Henry, W.J. Cantor // Interv. Cardiol. Clin. – 2016. – Vol. 5, N 4. – P. 439-450.
4. Peterson M.C. A systematic review of factors predicting door to balloon time in ST-segment elevation myocardial infarction treated with percutaneous intervention / M.C. Peterson, T. Syndergaard, J. Bowler, R. Doxey // Int. J. Cardiol. – 2012. – Vol. 157. – P. 8-23.
5. Ranasinghe I. Comparative effectiveness of population interventions to improve access to reperfusion for ST-segment-elevation myocardial infarction in Australia / I. Ranasinghe, F. Turnbull, A. Tonkin [et al.] // Circ. Cardiovasc. Qual Outcomes. – 2012. – Vol. 5. – P. 429-436.